Cempra Announces Full Exercise of Additional Share Option and Completion of the Public Offering of Common Stock
13 janv. 2015 16h01 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 13, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Prices Public Offering of Common Stock
07 janv. 2015 20h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Proposed Public Offering of $100 Million of Common Stock
05 janv. 2015 16h02 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Positive Topline Phase 3 Clinical Results for Oral Solithromycin in the Treatment of Community Acquired Bacterial Pneumonia
04 janv. 2015 17h00 HE
|
Melinta Therapeutics, Inc.
Solithromycin met the primary and secondary objectives of non-inferiority compared to moxifloxacin
Cempra to host webcast and conference call on January 5, 2015 at 8:00 a.m. EST
CHAPEL HILL,...
Cempra to Participate in Upcoming Investor Events in December
03 déc. 2014 16h10 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
19 nov. 2014 06h00 HE
|
Melinta Therapeutics, Inc.
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract
Phase 1b and Phase 2/3 Studies Will Test Intravenous, Oral Capsule and Oral Suspension...
Cempra to Present at Two Upcoming Investor Conferences
10 nov. 2014 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2014 Financial Results and Provides Corporate Update
29 oct. 2014 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2014 Financial Results and Host Webcast and Conference Call on October 29, 2014
22 oct. 2014 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...